Favorable outcome of PML‐RARα short isoform and FLT3‐ITD mutation in a patient with several adverse prognostic markers: A case report

Abstract

Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) that has a distinctive molecular pathophysiology and clinical manifestations. It is cytogenetically characterized by reciprocal translocation of promyelocytic leukemia (PML) gene at chromosome 15 and the retinoic acid receptor alpha (RARα) gene at chromosome 17 leading to the termination of maturation at the promyelocyte stage. 1,2 Prior to the introduction of ATRA

Advancements in Myeloid Leukemia Treatment: A Comprehensive Update

“…The WHO classification takes into account not only morphological features but also genetic and molecular abnormalities [18]. According to the WHO classification, AML is divided into several subtypes, including acute promyelocytic leukemia (APL), acute erythroid leukemia (AEL), acute megakaryocytic leukemia (AMKL), and others.APL is a distinct subtype of AML characterized by the presence of the PML-RARA fusion gene resulting from the t(15;17) translocation [19][20][21]. APL is associated with a favorable prognosis and is treated differently from other subtypes of AML [19].…”